Aptahem’s latest patent application is registered in several countries
Aptahem today informs that the company’s latest patent application has been registered in several countries and are subject to approval. The patent application, which is an international PCT application*, is a merger of two previous Europe applications and have now entered a so called country phase where the company has selected the most value increasing geographies. The patent application refers to Apta-1 and has the title ”A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties”.The patent application was submitted in 2017 after acheiving new,